Literature DB >> 28080255

Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.

Ruggero Capra1, Cinzia Cordioli1, Sarah Rasia1, Fabio Gallo2, Alessio Signori2, Maria Pia Sormani2.   

Abstract

OBJECTIVE: To assess whether the age at which multiple sclerosis (MS) patients reach Expanded Disability Status Scale (EDSS) milestones changed as long as new drugs for the treatment of MS became available.
METHODS: We evaluated the long-term impact of therapies on disability progression assessing whether there is a detectable delay in the age at which patients reached EDSS milestones in more recent years. We used data collected over more than 30 years in the Center of Brescia, Italy. We compared the age at EDSS = 6 among patients diagnosed with relapsing-remitting MS in different time periods, adjusting for age at diagnosis and median interval among EDSS visits, by a multivariate Cox model.
RESULTS: A total of 1324 MS patients were included. Patients diagnosed in more recent periods reached EDSS = 6 at an older age: the rate at which patients reached EDSS = 6 in those diagnosed in 1991-1995 was similar to those diagnosed in 1980-1990 (hazard ratio ( HR) = 1.09, p = 0.68) and to those diagnosed in 1996-2000 ( HR = 0.85, p = 0.44), it was reduced by 37% in patients diagnosed in 2001-2005 ( HR = 0.63, p = 0.05), by 46% in patients diagnosed in 2006-2010 ( HR = 0.54, p < 0.02).
CONCLUSION: A clear modification of MS course is observed after 2000; among other causes, this can be associated to the changes in the treatment patterns experienced in those years.

Entities:  

Keywords:  Multiple sclerosis; long-term treatment effect; real life

Mesh:

Year:  2017        PMID: 28080255     DOI: 10.1177/1352458516687402

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Authors:  Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald
Journal:  Mult Scler Relat Disord       Date:  2020-11-23       Impact factor: 4.339

Review 2.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

3.  Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients.

Authors:  Sara Zarei; Irvin Maldonado; Laura Franqui-Dominguez; Cristina Rubi; Yanibel Tapia Rosa; Cristina Diaz-Marty; Guadalupe Coronado; Marimer C Rivera Nieves; Golnoush Akhlaghipour; Angel Chinea
Journal:  Surg Neurol Int       Date:  2019-10-11

Review 4.  Navigating choice in multiple sclerosis management.

Authors:  Ralf A Linker; Andrew Chan
Journal:  Neurol Res Pract       Date:  2019-02-28

5.  B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.

Authors:  Sabine Tacke; Stefan Braune; Damiano M Rovituso; Tjalf Ziemssen; Paul V Lehmann; Heidi Dikow; Arnfin Bergmann; Stefanie Kuerten
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-03-11

Review 6.  The need for a strategic therapeutic approach: multiple sclerosis in check.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Ther Adv Chronic Dis       Date:  2022-01-18       Impact factor: 5.091

7.  Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.

Authors:  Paolo Angelo Cortesi; Ippazio Cosimo Antonazzo; Claudio Gasperini; Mihaela Nica; Daniela Ritrovato; Lorenzo Giovanni Mantovani
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

8.  Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.

Authors:  Arnon Karni; Gil Ben Noon; Tamara Shiner; Ifat Vigiser; Hadar Kolb; Keren Regev
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

9.  The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  J Neurol       Date:  2020-10-22       Impact factor: 4.849

10.  Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Authors:  Gavin Giovannoni; Giancarlo Comi; Kottil Rammohan; Peter Rieckmann; Fernando Dangond; Birgit Keller; Dominic Jack; Patrick Vermersch
Journal:  Adv Ther       Date:  2021-08-09       Impact factor: 4.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.